首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1290432

全球阿尔茨海默病药物市场 - 2023-2030年

Global Alzheimer Drugs Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球阿尔茨海默病药物市场在2022年达到39.7亿美元，预计到2030年将见证有利可图的增长，达到77亿美元。在2023-2030年的预测期内，全球阿尔茨海默病药物市场预计将呈现8.7%的复合年增长率。

全球阿尔茨海默氏症药物市场正在扩大，原因包括慢性疾病（包括痴呆症）的发病率不断增加，治疗管道的规模不断扩大，用于诊断和药物开发的生物标志物的支出，以及为早期检测创造更复杂的诊断方法。

阿尔茨海默症药物市场的药物类型范围包括阿尔茨海默症药物，如多奈哌齐、加兰他明、里瓦斯蒂明、美满霉素和其他，这增加了阿尔茨海默症药物类型的市场份额。这些药物可以减轻或调节一些行为和认知问题。阿尔茨海默病药物的发展和各国即将进行的医疗审批也为市场增长创造了积极的前景。

市场动态

在药物开发中使用生物标志物和大型管道推动了阿尔茨海默病药物市场的增长。

创造药物的风险很高，而生物标志物是降低风险和提高技术成功率的实用手段。对阿尔茨海默症的理解正在迅速发展，重要的生物事件现在正在被确认。通过大脑成像、血液或脑脊液（CSF）中可以看到的生物标志物可能偶尔会伴随这些事件的发生。

通过利用这些生物标志物来改善药物开发过程，有可能减少与阿尔茨海默氏症疗法的产生有关的风险。因此，生物标志物在开发阿尔茨海默氏症疗法中的意义越来越大，从而推动了阿尔茨海默氏症药物市场的发展。

不断增长的研究和开发以及阿尔茨海默症患病率的上升为制造商创造了有利可图的机会。

由于主要参与者在研究和开发能力方面进行了大量投资，以实现尖端技术的改进，因此存在着一个发展中的市场机会。影响市场的另一个趋势是对阿尔茨海默病治疗的需求不断增长。根据《世界阿尔茨海默病报告》，目前有5000万阿尔茨海默病或相关痴呆症患者，到2050年，这个数字预计将上升到1.52亿。

此外，美国食品和药物管理局已经授权使用两类药物，即胆碱酯酶抑制剂（Aricept, Exelon, Razadyne）和美满霉素（Namenda），来治疗阿尔茨海默病的认知副作用，如记忆丧失、迷失方向以及思考和推理问题。随着更多诊断和治疗阿尔茨海默病的临床试验的进行，市场将因此而上升。

晚期药物的高失败率将阻碍市场的增长

然而，由于高级药物的价格令人望而却步，后期阶段的探索性候选药物无能为力，以及贫穷国家对阿尔茨海默病的认识水平不高，全球阿尔茨海默病药物市场在预测期内可能受到制约。

例如，20222年11月，罗氏集团旗下的基因泰克公司发布了调查甘特纳鲁单抗用于阿尔茨海默病和轻度阿尔茨海默病痴呆症（一般称为早期阿尔茨海默病）导致的轻度认知障碍（MCI）患者的GRADUATE I和II III期研究的结果。该研究的主要目标是减少临床衰退，但没有实现。

COVID-19影响分析

COVID-19分析包括COVID前情景、COVID情景和COVID后情景，此外还有定价动态（包括大流行期间和之后的定价变化，与COVID前情景进行评估）、需求-供应谱（由于贸易限制、封锁和之后的问题导致的需求和供应转移）、政府倡议（政府机构重新激活市场、产业或部门的倡议）和制造商战略倡议。

俄乌战争影响分析

由于该地区的主要市场参与者数量较少，估计俄乌冲突对全球阿尔茨海默病药物市场的影响不大。然而，在预测期内，原材料进出口的影响预计对全球阿尔茨海默病药物市场的增长影响不大。

Market Overview

The Global Alzheimer Drugs Market reached US$ 3.97 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 7.7 billion by 2030. The global alzheimer drugs market is expected to exhibit a CAGR of 8.7% during the forecast period 2023-2030.

The global market for Alzheimer's medications is expanding due to factors including the increasing prevalence of chronic diseases, including dementia, the growing size of the therapeutic pipeline, expenditures in biomarkers for diagnosis and drug development, and the creation of more sophisticated diagnostics for early detection.

The Alzheimer drugs market's drug type scope comprises Alzheimer drugs like donepezil, galantamine, rivastigmine, memantine and others, which has increased the market share for Alzheimer drugs type. These medications could lessen or regulate some behavioral and cognitive issues. Alzheimer's drugs developments and upcoming medical approvals across countries are also creating a positive outlook for market growth.

Market Dynamics

Use of Biomarkers in Drug Development and Large Pipeline Drive the Growth of the Alzheimer Drugs Market.

The risk involved in creating medication is high, and biomarkers present a practical means of reducing the risk and enhancing technical success. The understanding of Alzheimer is rapidly developing, and important biological events are now being identified. Biomarkers that can be seen by brain imaging, in the blood or in the cerebrospinal fluid (CSF) may occasionally accompany these occurrences.

By utilizing these biomarkers to improve the drug development process, it may be possible to reduce the risk associated with the creation of Alzheimer therapies. As a result, the market for Alzheimer's pharmaceuticals is being driven by the increasing significance of biomarkers in developing AD therapies.

Growing Research and Development and Rising Prevalence of Alzheimer Creates Lucrative Opportunities for Manufacturers.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for Alzheimer treatment. According to the World Alzheimer Report, there are currently 50 million people living with Alzheimer's disease or related dementia, and by 2050, that number is expected to rise to 152 million.

Additionally, the FDA has authorized the use of two pharmacological classes, cholinesterase inhibitors (Aricept, Exelon, Razadyne), and memantine (Namenda), to treat the cognitive side effects of Alzheimer's disease, such as memory loss, disorientation, and problems with thinking and reasoning. With more clinical trials being conducted for the diagnosis and treatment of Alzheimer's, the market will rise as a result.

High failure Rates of Late-Stage Drugs will Hamper the Growth of the Market

The global marketplace for Alzheimer's drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low level of knowledge of Alzheimer's disease in poor countries.

For instance, in November 20222, results from the GRADUATE I and II Phase III studies investigating gantenerumab in patients with mild cognitive impairment (MCI) owing to Alzheimer's and mild Alzheimer's dementia, generally known as early Alzheimer's disease, were released by Genentech, a member of the Roche Group. The research' main goal of decreasing clinical decline was not achieved.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global alzheimer drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global alzheimer drugs market growth over the forecast period.

Segment Analysis

The Global Alzheimer Drugs Market is segmented based on drug type, distribution channel and region.

Hospital Pharmacy from the Distribution Channel Segment Accounts for 40.1% of Market Share. Owing to Rising Hospital Admissions

The goal of hospital pharmacy is to constantly maintain and improve patient medication administration to the greatest levels imaginable. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. One of the goals is to enhance patient outcomes through the prescription, procurement, distribution, management, and review of medications.

Hospital pharmacies will see an increase in demand thanks to benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use (such as injections, suppositories, and nasal sprays), and making sure the container can be read and opened with ease. identifying potential health issues unrelated to dementia. Hence above-mentioned factors prove that hospital pharmacies will be the largest market shareholder.

Geographical Analysis

North America accounted for approximately 39.2% of the market share due to major players' strong presence and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for Alzheimer drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of Alzheimer drugs, increasing demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of Alzheimer drugs applications. Rising new product launches for using in patients with dementia or Alzheimer will drive the market growth.

Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for Alzheimer such as biomarkers, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the alzheimer drugs market include: F. Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, AbbVie, Siemens Healthineers and Lupin among others.

Why Purchase the Report?

To visualize the Global Alzheimer Drugs Market segmentation based on drugs type, distribution channel and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Alzheimer drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Alzheimer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drugs Type
3.2. Snippet by Distribution Channel
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Use of biomarkers in drug development and large pipeline
  - 4.1.1.2. Large number of drugs in pipeline
- 4.1.2. Restraints
  - 4.1.2.1. High failure rates of late-stage drugs
- 4.1.3. Opportunity
  - 4.1.3.1. Growing research and development and rising prevalance of Alzheimer
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Drugs Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 7.1.2. Market Attractiveness Index, By Drugs Type
7.2. Donepezil *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Galantamine
7.4. Rivastigmine
7.5. Memantine
7.6. Others

8. By Distribution Channel

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan

Australia

9.5.5.4. Rest of Asia-Pacific

9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. F. Hoffmann-La Roche *
- 11.1.1. Company Overview
- 11.1.2. Drugs Type Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Novartis AG
11.3. Merck & Co.
11.4. Pfizer Inc.
11.5. Eli Lily and Co.
11.6. Biogen Inc.
11.7. Johnson & Johnson
11.8. Lupin
11.9. AbbVie Inc.
11.10. Siemens Healthineers

LIST NOT EXHAUSTIVE

12. Appendix

12.1. About Us and Services
12.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格